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ABSTRACT 36 
Human Leukocyte Antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all 37 
individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer 38 
types via the monomorphic MHC class I related protein, MR1, while remaining inert to non-cancerous cells. Unlike mucosal-associated invariant 39 
T (MAIT) cells, recognition of target cells by the TCR was independent of bacterial loading. Furthermore, concentration-dependent addition of 40 
 3
vitamin B-related metabolite ligands of MR1 reduced TCR recognition of cancer cells suggesting that recognition occurred via sensing of the 41 
cancer metabolome. An MR1 restricted T cell clone mediated in vivo regression of leukemia and conferred enhanced survival of NSG mice. TCR 42 
transfer to patient T cells enabled killing of autologous and non-autologous melanoma. These findings offer opportunities for HLA-independent, 43 
pan-cancer, pan-population immunotherapies.  44 
 45 
INTRODUCTION 46 
Unconventional T cells do not recognize classical peptide-Major Histocompatibility Complex (pMHC) ligands and can express αβ or γδ T cell 47 
receptors (TCRs). The ligands recognized by many unconventional T cells remain unknown. Established unconventional T cell ligands include lipid 48 
antigens presented by the conserved CD1 family of molecules, as recognized by Natural Killer T (NKT) cells and Germline-Encoded Mycolyl-lipid 49 
reactive T (GEM) cells. The human Vγ9Vδ2 T cell subset recognizes phosphorylated isoprenoid intermediates of lipid biosynthesis in the context 50 
of Butyrophilin 3A11. The concept of T cell sensing of intracellular biosynthetic pathways was recently extended by the discovery that MAIT cells 51 
sense microbial metabolites bound to the evolutionarily-conserved, monomorphic MHC-class 1 related protein (MR1)2,3. MAIT cell stimulatory 52 
antigens have been defined as riboflavin-derived derivatives produced by a range of bacteria and fungi4, notably 5-(2-oxopropylideneamino)-6-53 
D-ribitylaminouracil (5-OP-RU)5. MAITs can rapidly clear pathogens through secretion of a range of cytokines that can be accompanied by 54 
granzyme and perforin expression upon recognition of these antigens bound to MR16. MAITs are defined by their semi-invariant TCR gene 55 
segment usage consisting of TRAV1-2 rearranged with TRAJ33, 12 or 20, paired with a limited repertoire of TCR-β chains4,7,8, including but not 56 
limited to TRBV6 and TRBV20. More recent evidence shows that recognition of MR1-associated ligands can be accomplished by a wider range of 57 
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TCR rearrangements including those using TRAV14, TRAV21 and TRAV36 chains and that MR1 can present a broader range of ligands than those 58 
from the riboflavin biosynthetic pathway, incorporating diverse chemical scaffolds which includes drugs and drug-like molecules9–13. In 59 
combination, these data suggest that MR1 presents a wide range of metabolic intermediates at the cell surface in much the same way as MHC 60 
molecules present arrays of peptides, and the CD1 family of molecules present various lipid antigens. T cell targeting of diseases via MHC Ib and 61 
MHC-I like molecules such as CD1 and MR1 is especially attractive as, unlike the highly polymorphic human leukocyte antigen (HLA) targets of 62 
conventional T cells, these molecules are largely monomorphic in the human population. Indeed, MR1 is ubiquitously expressed and the 63 
currently known non-peptide ligands it presents cannot mutate as they are essential biosynthetic intermediates to many microbes14. While most 64 
studies have indicated MR1 is only expressed on the cell surface after an MR1-binding ligand has bound14,15 there is evidence that there is a basal 65 
surface expression, including on cancer cells9,16. Intratumoural unconventional T cell infiltrations have also been associated with favorable 66 
prognostic outcome17, with MAIT cells also shown to have a role in multiple myeloma18. Human MR1 has a very limited number of silent and 67 
intronic polymorphisms19,20 and natural isoforms21, highlighting its potential as a pan-population target. Currently, there are no self-ligands 68 
identified that bind to MR1 that induce a T cell response. However, there is increasing evidence that populations of MR1-restricted cells exist 69 
that likely respond to self-antigens9,16. These MR1-restricted T cells are not classical MAIT cells in that they do not appear to possess a TRAV1-2 70 
TCR nor do they react to bacterial antigens bound to MR1. Here we report of a novel non-MAIT TCR that recognizes a non-bacterial antigen 71 
restricted by MR1 resulting in lysis of cancer cells. This TCR does not respond to healthy cells but confers HLA-independent recognition to a wide 72 
range of cancer cells. 73 
 74 
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RESULTS 75 
Clone MC.7.G5 kills a broad range of cancer cells regardless of HLA allomorph 76 
A T cell population that proliferated in response A549 cancer cells was grown from the peripheral blood mononuclear cells from an HLA-77 
mismatched healthy donor (Fig. 1a). Recognition of A549 cells by the αβTCR+ γδTCRneg CD8α+CD8βlowCD4neg (Supplementary Fig. 1a) T cell clone 78 
MC.7.G5 grown from this line was not reduced by blocking MHC antibodies (Fig. 1b). TCR sequencing of MC.7.G5 confirmed expression of an 79 
αβTCR; comprised of a TRAV38.2/DV8 TRAJ31 α-chain paired with a TRBV25.1 TRBJ2.3 β-chain (Supplementary Fig. 1b). MC.7.G5 killed multiple 80 
cancer cell lines tested (lung, melanoma, leukemia, colon, breast, prostate, bone and ovarian) that did not share a common HLA (Fig. 1c). 81 
MC.7.G5 also killed minimally-cultured primary ovarian and melanoma cancer cells, indicating that killing was not an artifact of long-term culture 82 
(Fig. 1c). MC.7.G5 remained inert to healthy cells (Fig. 1d) and showed high sensitivity to a melanoma target at low effector to target ratios (Fig. 83 
1e). As MC.7.G5 preferentially killed cancer cells independently of classical MHC molecules we set-out to uncover its mechanism of action.  84 
 85 
Genome-wide CRISPR-Cas9 screening revealed MR1 as the MC.7.G5 target on cancer cells 86 
As MC.7.G5 killed a wide range of cancer cell lines originating from different tissues and organs regardless of their HLA allomorph expression, its 87 
mode of target cell recognition was unclear. A genome-wide CRISPR-Cas9 approach, using the GeCKOv.2 library22,23 which targets every protein-88 
coding gene in the human genome with six different single guide (sg)RNAs, was used to identify genes essential for recognition of target cells by 89 
MC.7.G5 (Fig. 2a). Following two rounds of selection with MC.7.G5 the surviving transduced HEK293T cells exhibited reduced capacity to 90 
stimulate MC.7.G5, suggesting key genes involved in their recognition had been ablated (Fig. 2b). Sequencing of the CRISPR sgRNAs in the lysis-91 
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resistant HEK293T cells showed that only 6 genes were targeted by more than one enriched sgRNA: β2M (five sgRNAs), MR1 (two sgRNAs), 92 
regulatory factor X (RFX, five sgRNAs), RFX associated ankyrin containing protein (RFXANK, five sgRNAs), RFX associated protein (RFXAP, three 93 
sgRNAs), and signal transducer and activator of transcription 6 (STAT6, two sgRNAs) (Fig. 2c). RFX, RFXANK and RFXAP are essential components 94 
of the protein complex responsible for transactivating β2M, MHCI and MHCII promoters24. Combined with the fact that β2M and MR1 95 
heterodimerise to form a monomorphic stable antigen-presenting molecule known to activate MAITs and other MR1-restricted T cells, these 96 
data strongly suggested that the MC.7.G5 T cell recognized cancer targets via the MR1 molecule. Accordingly, anti-MR1 antibody, but not MHCI 97 
or MHCII antibodies, blocked target cell recognition by MC.7.G5 (Fig. 3a). CRISPR-mediated knockout of MR1 from A54911 and melanoma 98 
MM909.24 (frame-shift deletion mutation shown in Supplementary Fig. 2a) protected against MC.7.G5-mediated recognition and lysis (Fig. 3b). 99 
Melanoma MM909.24 did not stain with anti-MR1 antibody suggesting that very minimal levels of MR1 were required for target recognition 100 
(Supplementary Fig. 2b). Overexpression of MR1 resulted in strong recognition of the poorly recognized targets, HeLa and C1R (MR1 staining in 101 
Supplementary Fig. 2b), and slightly enhanced recognition of melanoma MM909.24 (Fig. 3c). Reintroduction of MR1 in to CRISPR-Cas9 MR1-102 
knockout A549 cells under a CMV promoter11 restored recognition by MC.7.G5 (Fig. 3d), instilling further confidence that cancer cell recognition 103 
was MR1-dependent. In summary, whole genome CRISPR screening effectively revealed MR1 as the restricting molecule on cancer cells for the 104 
HLA-agnostic T cell clone MC.7.G5.  105 
 106 
MC.7.G5 does not recognise MR1 by known mechanisms 107 
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MR1 is known to present intermediates in riboflavin synthesis at the cell surface to MAIT cells and is not considered to be expressed appreciably 108 
at the cell surface without a bound cargo14. MC.7.G5 did not stain with tetramers composed of MR1 containing the K43A mutation that allows 109 
MR1 refolding without bound ligand (Fig. 4a)13. Accordingly, MC.7.G5 did not recognize C1R cells transduced with the MR1 K43A mutant (Fig. 4b) 110 
despite high overexpression of surface MR1 K43A detectable by anti-MR1 antibody staining (Supplementary Fig. 2b). This demarcates MC.7.G5’s 111 
recognition of target cells from the previously described ‘MR1T’ cells that do not require K43 for activation9. The requirement for the ligand-112 
binding K43 suggested that MC.7.G5 might recognize an MR1-bound ligand that was specifically expressed or upregulated in malignant cells. In 113 
concordance with this hypothesis, MC.7.G5 did not stain with tetramers assembled with MR1 presenting microbial derived T cell activator 5-OP-114 
RU (Fig. 4a). Furthermore, recognition of target cells was reduced when loaded with either the MAIT activating bacterium Mycobacterium 115 
smegmatis (M. smeg) or Salmonella enterica serovar Typhimurium (Fig. 4c&d), or MR1 ligand Acetyl-6-Formylpterin (Ac-6-FP)11,25 (Fig. 4e), 116 
despite a slight increase in surface expression of MR1 (Supplementary Fig. 2c). MC.7.G5 exhibited cancer specificity unlike the majority of  MR1T 117 
cells9, which require over-expression of MR1 for optimal target cell recognition and also activated in response to MR1 expression by healthy 118 
monocyte derived dendritic cells.  MC.7.G5 did not recognize immature or matured monocyte derived dendritic cells (Fig. 5a), nor Langerhans 119 
cells (Fig. 5b). These results indicate that MC.7.G5 does not exclusively recognize MR1 per se, nor MR1 by known mechanisms, but rather MR1 120 
with bound cargo that is specific to, or associated with, cancer cells. A MC.7.G5-like T cell clone was grown from a second donor, which was also 121 
dependent on K43 for target cell recognition (Supplementary Fig. 3), suggesting that cancer-specific T cells capable of recognizing wild-type 122 
levels of MR1 may be present in multiple individuals. 123 
 124 
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MC.7.G5 remained inert to resting, activated, stressed or infected healthy cells from various tissues  125 
In order to assess the safety of using the MC.7.G5 TCR for cancer immunotherapy we undertook further testing of healthy cells from various 126 
tissues. In extension to the data shown in Fig. 1 (smooth muscle, lung fibroblast and liver cells) and Fig. 5a&b (dendritic and Langerhans cells), 127 
MC.7.G5 did not kill healthy cells from lung (alveolar and bronchus), skin (melanocytes), intestine, pancreas or kidney (Fig. 5c). In the same assay 128 
>95% of each cancer cell line from lung, skin (melanomas), blood, cervix and kidney were killed, whereas cancer cell lines rendered negative for 129 
MR1 using CRISPR-Cas9 were not killed (Fig. 5c). Next, we created conditions that may induce cellular upregulation of cell surface MR1, or 130 
generate ligands bound to MR1. T or B cells sorted directly ex vivo and activated overnight with either PHA or TLR9 ligand respectively (CD69 131 
staining, Supplementary Fig. 4a) were untouched by MC.7.G5 (Fig. 6a). Lymphoblastoid cell lines that are relatively poor targets of MC.7.G5, did 132 
not activate MC.7.G5 following treatment with tert-Butyl hydroperoxide (tBHP) (Fig. 6b) to induce cell stress (ROS detection, Supplementary Fig. 133 
4b). Furthermore, a normal renal epithelial cell line did not become targets when treated with tBHP or H2O2 (ROS detection, Supplementary Fig. 134 
4b), which induce different pathways of cell stress26, or by exposure to γ-irradiation (Fig. 6b). M. smeg infection of healthy lung epithelial cells 135 
did not lead to MC.7.G5 activation, whereas the infected cells were recognized by a MAIT T cell line (Fig. 6c). Therefore, healthy cells are 136 
incapable of activating MC.7.G5, even when stressed or damaged. 137 
 138 
MC.7.G5 controls leukemia in vivo 139 
To examine the in vivo capacity of MC.7.G5 to target cancer, Jurkat leukemia cells were engrafted in NSG mice followed by the adoptive transfer 140 
of MC.7.G5. Bone marrow samples were analyzed for MC.7.G5 and Jurkat cell frequencies at days 12 and 18 post T cell transfer. MC.7.G5 141 
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appeared in the bone marrow at both time points but the number of cells remaining on day 18 following the single transfusion was substantially 142 
reduced (Fig. 7a). Mice receiving MC.7.G5 had significantly less Jurkat cells at days 12 and 18 (Fig. 7a) than mice with no MC.7.G5. The difference 143 
in Jurkat cell burden was particularly striking at day 18 with mice receiving MC.7.G5 having 3.8%, 7.2% and 0.3% Jurkat cells in the bone marrow, 144 
compared to 83%, 78% and 85% for the mice without MC.7.G5 (Fig. 7a). The presence of Jurkat cells was also reduced in the spleen of mice that 145 
received T cells, with a similar drop in T cell numbers by day 18 (Supplementary Fig. 5). The in vivo targeting of Jurkat cells by MC.7.G5 was 146 
dependent on MR1 expression, as shown by co-transfer experiments with differentially labelled Jurkat wild-type and Jurkat MR1–/– cells to the 147 
same mice (Fig. 7b). The ability of MC.7.G5 to target Jurkat cells in vivo translated to a significant enhancement of survival for mice that received 148 
T cells (Fig. 7c). These data demonstrate that MC.7.G5 maintained its reactivity towards cancer cells in an in vivo setting thus reducing cancer 149 
burden and enhancing survival. 150 
 151 
The MC.7.G5 redirects patient T cells to kill autologous cancer cells 152 
To explore the therapeutic potential of targeting MR1 on cancer cells we purified T cells from the PBMCs of Stage IV melanoma patients and 153 
lentivirally transduced them with the MC.7.G5 TCR (≥85% expression, Supplementary Fig. 6a), which resulted in recognition and killing of 154 
autologous and non-autologous melanomas (Fig. 8a&b), but not healthy cells (Fig. 8b). The killing was specific to MR1 as the MC.7.G5 TCR 155 
transduced cells did not lyse MR1 knockout melanomas (Fig. 8b). We conclude that the MC.7.G5 TCR can redirect patient T cells to kill patient 156 
cancer cells without the requirement of a specific HLA. 157 
 158 
159 
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DISCUSSION 160 
 161 
MR1 is an attractive target for cancer immunotherapy due to its monomorphic, ubiquitously-expressed nature. Recent advances in MR1 162 
tetramers and ligand discoveries have progressed knowledge in this area but there is still much to be discovered. Here we confirmed cancer cell 163 
recognition by a T cell clone that responded to multiple cancer cell lines from diverse tissue types, resulting in killing of cancer cells in vitro and in 164 
vivo. The clone expresses a TCR that is not indicative of MAIT cells. Current MR1 antibodies are unable to detect low surface expression of MR1 165 
on cancer cells, despite detectable mRNA expression15. Indeed, the level of MR1 surface expression required for cancer cell recognition by 166 
MC.7.G5 was often below the threshold required for staining with antibody, suggesting that the MC.7.G5 TCR might be capable of responding to 167 
a low copy number of MR1 ligand, akin to T cells that recognize pMHC and MAIT TCR recognition of MR127. Our results also demonstrate the 168 
immense power of genome-wide CRISPR-Cas9 screening as a discovery platform for unconventional T cell ligands and we anticipate that the 169 
methodologies applied here will rapidly revolutionize the unconventional T cell field by revealing new ligands. Further work will be required to 170 
establish the exact nature of the ligand recognized by the MC.7.G5 TCR. Knowledge of known MR1-restricted ligands suggests that the MC.7.G5 171 
TCR ligand may be a cancer-specific or -associated metabolite. We failed to find hits in a metabolic pathway during our genome-wide CRISPR-172 
Cas9 screens. This suggests that the MR1-associated ligand targeted by the MC.7.G5 TCR is part of a pathway essential for the basic survival of 173 
cancer cells and therefore not amenable for the gene disruption required for CRISPR-Cas9 screening. 174 
 175 
In summary, we describe a TCR that exhibits pan-cancer cell recognition via the invariant MR1 molecule, and by equipping melanoma patient T 176 
cells that lacked detectable cancer cell reactivity with the MC.7.G5 TCR, rendered them capable of killing autologous melanoma. Importantly, 177 
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MC.7.G5 did not respond to healthy cells and caused no obvious pathology in the healthy donor it was grown from. Since the MC.7.G5 TCR can 178 
recognize disperse cancer cell type, including primary cancer cells, irrespective of HLA it opens up exciting opportunities for pan-cancer, pan-179 
population T cell-mediated cancer immunotherapy approaches. Discovery of the MR1-restricted ligands recognized by MC.7.G5-like T cells may 180 
further open up opportunities for therapeutic vaccination for many cancers in all individuals.  181 
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 268 
Legends 269 
Figure 1: MC.7.G5 recognises multiple cancer types through an HLA-independent mechanism. (a) MC.7.G5 was cloned from T cells that 270 
proliferated in response to cancer cell line A549. Performed once for this donor. (b) MC.7.G5 did not recognise A549 through MHCI or MHCII. 271 
Overnight activation +/- blocking antibodies and TNF ELISA. Bars depict the mean. (c) MC.7.G5 killed a range of established (long-term culture) 272 
and primary cancer cell lines of different origin. Flow-based killing assay for 48-72h at a T cell to target cell ratio of 5:1. Data combined from 273 
different experiments. Performed in triplicate. (d) MC.7.G5 killed melanoma cells but not healthy cells. Flow based killing assay at a T cell to 274 
target cell ratio of 5:1. Performed in triplicate or duplicate (fibroblasts). (e) MC.7.G5 sensitively killed melanoma MM909.24 over 7 days. 275 
Performed in duplicate. b-e Bars, horizontal lines and connecting line depict the mean. 276 
 277 
Figure 2: Whole genome CRISPR-Cas9 library screening reveals MR1 as the candidate target of MC.7.G5. (a) Overview of the approach used to 278 
reveal the ligand of MC.7.G5. GeCKO v2 whole genome CRISPR-Cas9 libraries A and B were used as lentivirus to transduce target cell line 279 
HEK293T. MC.7.G5 lysed HEK293T expressing sgRNAs for genes that are irrelevant for HEK293T recognition, thereby enriching sgRNAs for genes 280 
that are essential for cancer cell lysis by MC.7.G5. Two rounds of selection with MC.7.G5 were performed and comparison of selected libraries 281 
unselected HEK293T (no MC.7.G5) revealed enriched sgRNAs. (b) MC.7.G5 recognition of selected HEK293T library post-selection is greatly 282 
reduced compared to wild-type HEK293T, suggesting key genes had been ablated by the whole genome CRISPR-Cas9 approach. Overnight 283 
activation and TNF ELISA, performed in duplicate. Bars depict the mean. (c) MR1 was identified as one of key genes for MC.7.G5 recognition of 284 
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HEK293T. Total genomic DNA from 3 x107 selected and unselected HEK293T libraries was used for sequencing, followed by MAGeCK analysis. 285 
Highlighted (coloured) genes with y genes for MC.7.G5 recognition of HEK293T.reduced 286 
 287 
Figure 3. MR1 is the cancer cell expressed target of MC.7.G5. (a) Recognition of melanoma MM909.24 was reduced in the presence of MR1 288 
blocking antibody (Ab). MHCI and II Abs were used as negative controls. Overnight activation and TNF ELISA. (b) Removal of MR1 expression 289 
(CRISPR/Cas9) from cancer cell lines prevented MC.7.G5 mediated recognition and killing. Overnight activation and TNF ELISA or chromium 290 
release cytotoxicity assay. (c) Lentiviral overexpression (+) of MR1 in poor targets of MC.7.G5 improved target cell killing by MC.7.G5. Chromium 291 
release cytotoxicity assay. (d) Lentiviral expression of MR1 in MR1
-/- 
cells restores activation of MC.7.G5. TNF ELISA. Conditions performed in 292 
duplicate. Bars depict the mean. 293 
 294 
Figure 4. MC.7.G5 does not recognise MR1 by known mechanisms. (a) MC.7.G5 did not stain with empty (K43A) or MR1 5-OP-RU tetramers. A 295 
canonical MAIT clone recognizes MR1 bound with 5-OP-RU. The MHCI-restricted clone was used as a positive control for the irrelevant MHCI 296 
tetramer. Performed twice with similar results. (b) MC.7.G5 recognised target cells over-expressing wildtype MR1 (MR1
++
) but not K43A mutated 297 
MR1. Overnight activation performed in duplicate and TNF ELISA. (c) Loading with MAIT-activating bacterium Mycobacterium smegmatis 298 
(M.smeg) reduced MC.7.G5 recognition of A549 cells. Canonical MAIT clone used as a positive control. Staining for surface CD107a and 299 
intracellular TNF. Performed twice with similar results. (d) M. smeg and Salmonella enterica serovar Typhimurium (S.Typhimurium) reduced 300 
MC.7.G5 recognition of A549 cells. Overnight activation and TNF ELISA. (e) Exogenous Ac-6-FP, a known MR1 binding molecule, reduced 301 
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MC.7.G5 recognition of melanoma MM909.24. Percentage of cell triple positive for the markers shown is plotted. Performed twice with similar 302 
results.  303 
 304 
Figure 5. MC.7.G5 does not recognise healthy cells. (a) MC.7.G5 did not recognize immature or matured monocyte (mo) derived dendritic cells 305 
(DCs). Overnight activation and TNF ELISA. (b) MC.7.G5 did not recognize matured Langerhans cells. CD1a-restricted clone 40E.22 used as a 306 
positive control for recognition of Langerhans cells. Overnight activation and TNF ELISA. (c) Cancer cell lines lacking MR1 (CRISPR/Cas9) and 307 
healthy cells from various tissues were not killed by MC.7.G5. Flow-based killing assay (48h 1:1 ratio). Performed in triplicate. a-c bars depict the 308 
mean. 309 
 310 
Figure 6. MC.7.G5 remained inert to activated, stressed or infected healthy cells. (a) T cell (Jurkat) and B cell (K562) cancer cells were targets of 311 
MC.7.G5, whereas whole PBMCs and resting or activated purified T and B cells were not killed. Flow-based killing assay (24h 1:1 ratio). 312 
Performed in triplicate. (b) Experiment 1: tert-Butyl hydroperoxide (tBHP) treatment to induce stress in poor targets (C1R and SAR26 313 
lymphoblastoid cell lines) of MC.7.G5 did not lead to T cell activation. MC.7.G5 recognition of melanoma MM909.24 +/- MR1 was unaffected by 314 
tBHP treatment. Experiment 2: Healthy renal epithelial cells were not recognised by MC.7.G5 following treatment with either tBHP or hydrogen 315 
peroxide (H202), or after exposure to ߛ-irradiation. Overnight activation and TNF ELISA. Inserted histogram of irradiated renal cells stained with 316 
the viability dye VIVID showing cell death after irradiation compared to un-irradiated cells. (c) Mycobacterium smegmatis infected healthy lung 317 
epithelial cells did not lead to MC.7.G5 activation, whereas a MAIT line recognised the infected cells. Uninfected or infected A459 cells +/- MR1 318 
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acted as controls for MC.7.G5 and the MAIT line respectively. The MAIT line exhibited some recognition towards the uninfected lung cells. TAPI-0 319 
assay for 4h. Percentage shown for duplicate conditions. Performed twice with similar results. a-c bars depict the mean. 320 
 321 
Figure 7. MC.7.G5 mediates in vivo regression of leukemia and prolongs the survival of mice. (a) NSG mice received Jurkat cells (3 x106) then a 322 
single infusion of MC.7.G5 (1.5 x106) 7 days later. MC.7.G5 reduced Jurkat cells in bone marrow cells at day 12 (n=10) and 18 (n=6) post T cell 323 
transfer (left axis). P values (* 0.032 ** 0.0038) from a two-sided non-parametric two-sample Kolmogorov-Smirnov test. Horizontal line depicts 324 
mean and error bars the SD. Jurkat cells did not appear in the spleen at day 12 but MC.7.G5 reduced Jurkat cell load by day 18. Few MC.7.G5 325 
cells were recovered from the bone marrow 18 days after single infusion (right y-axis), and also from the spleen. (b) WT MR1 expressing Jurkat 326 
cells were preferentially targeted in mice receiving MC.7.G5. The same number of MR1 WT and MR1
-/- 
(DsRed-Express2+) Jurkat cells (4 x106 in 327 
total) were co-transferred to the same mouse (n=7 per group) followed 7 days later by 3 x106 MC.7.G5. Splenocytes were harvested on day d25 328 
post T cell transfer. (c) Enhanced survival of mice with Jurkat cancer that received MC.7.G5. 8 mice per group (+/- T cells). Experimental set-up as 329 
in (a). Mice were culled when they had lost 15% of their original body weight as required by UK Home Office rules. Median survival of 60.5 and 330 
30.5 days for +/- T cells respectively. Logrank two-sided p value (**** 0.000066) and Hazard Ratio (4.54, 1.27-16.21) were calculated using the 331 
MatSurv survival analysis function in Matlab, availableilabhttps://www.github.com/aebergl/MatSurv.  332 
 333 
Figure 8. Transfer of the MC.7.G5 T cell receptor redirects patient T cells to recognise autologous melanoma. (a) Metastatic melanoma patient 334 
(MM909.11 and MM909.24) derived T cells transduced with the T cell receptor of MC.7.G5 recognised autologous and non-autologous 335 
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melanomas. Surface CD107a and intracellular TNF after 4h. Performed twice with similar results. (b) T cells from patient MM909.11 transduced 336 
with MC.7.G5 TCR killed autologous and non-autologous melanomas, but not healthy cells. Flow-based killing assay for 36h at a T cell to target 337 
cell ratio of 5:1. Bars depict the mean. 338 
 339 
 340 
Methods  341 
Patient and human tissue 342 
Stage IV metastatic melanoma patients MM909.11 and MM909.24 underwent rapid tumor infiltrating therapy for at the Centre for Cancer 343 
Immunotherapy (CCIT), Herlev Hospital, Copenhagen (ethics reference EudraCT no. 2008-008141-20). Ovarian cancer ascites was sourced 344 
through the Wales Cancer Bank (ethics reference WCB14/004) from a stage 3 chemotherapy resistant patient (50001389) at Velindre Cancer 345 
Centre (Cardiff, United Kingdom). Blood was sourced from the Welsh Blood Service (Pontyclun, United Kingdom). The use of human blood was 346 
approved by the School of Medicine Research Ethics Committee (reference 18/56). All human blood was procured and handled in accordance 347 
with the guidelines of Cardiff University to conform to the United Kingdom Human Tissue Act 2004. All samples were taken with informed 348 
consent from participants. 349 
 350 
Cell lines  351 
Cell lines were regularly tested for mycoplasma, and cultured based on ATCC guidelines; breast adenocarcinomas MCF-7 (HTB-22™); prostate 352 
adenocarcinoma LnCAP (CRL-1740™); cervical adenocarcinomas HeLa (CCL-2™) and SiHa (HTB-36™); acute lymphoblastic leukaemia MOLT3 353 
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(CRL-1552™); chronic myeloid leukaemia K562 (CRL-3344™); myeloma/plasmacytoma U266 (TIB-196™); osteosarcoma U-2 OS (HTB-96™); 354 
immortalized embryonic kidney cell HEK293T (CRL-1573™); acute monocytic leukaemia THP-1 (TIB-202™); lung carcinoma A549 (CCL-185™); 355 
acute T cell leukaemia Jurkat (TIB-152™); colorectal adenocarcinoma COLO 205 (CCL-222™); and ovarian carcinoma A2780 (ECACC 93112519 for 356 
culture guidelines). Melanomas FM-45, MM909.11 and MM909.24, and renal cell carcinoma RCC17 were sourced from the CCIT, and MEL 624 357 
from in-house, with all being cultured in R10 (RPMI 1640 supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL 358 
streptomycin and 2 mM L-Glutamine (Life Technologies, Paisely, UK) at 37°C as adherent monolayers, passaged when 50-80% confluent using 2 359 
mM EDTA D-PBS to detach cells. C1R and lymphoblastoid cell line (LCL) SAR26 were sourced or generated in-house and cultured in R10 as 360 
suspension cells. The primary epithelial ovarian cancer cell line EOC031 was generated from ascites following previous guidelines28 with the 361 
following amendments: the ascites was diluted 1:10 with R10 and centrifuged to collect the cells, which were subsequently depleted of red 362 
blood cells and debris using standard density gradient centrifugation. DMEM-F12 media (Life Technologies) was supplemented as for R10 with 363 
the addition of 5% human serum. Once cells had attached to the flasks and grown for 3 days fibroblasts were removed by incubation with 364 
Trypsin/EDTA for 1 min leaving the ovarian cancer cells for assays. Primary melanomas lines MM909.11, MM909.20 and MM909.21 were 365 
sourced from the CCIT and used directly from cryopreserved samples for killing assays without prior culture. Normal/healthy cells and their 366 
proprietary culture media were obtained from Sciencell (Carlsbad, CA, USA): SMC3 (colonic smooth muscle); CIL-1 (non-pigmented bronchial 367 
ciliary epithelium); HH (hepatocyte); pulmonary alveolar epithelia; melanocytes; renal epithelia; and pancreatic stellate cells. MRC5s (fibroblast) 368 
were sourced locally and cultured as described by the ATCC. Intestinal epithelia and their media were sourced from Lonza (Basel, Switzerland). 369 
Dendritic cells and Langerhans were generated from CD14+ cells purified from PBMCs using magnetic beads (Miltenyi Biotec Ltd, Bisley, UK). 370 
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Briefly, both immature DCs and LCs were differentiated with GM-CSF (20 ng/mL) and IL-4 (10 ng/mL), sourced from Miltenyi Biotec Ltd, with LCs 371 
also receiving 20 ng/mL of TGFβ (Miltenyi Biotec Ltd), for 7-10 days before maturation for 48h with 20 ng/mL of TNF (Miltenyi Biotec Ltd). 372 
Healthy T and B cells were purified from PBMCs using CD3 (negative purification) or CD19 magnetic beads (Miltenyi Biotec Ltd), then activated 373 
with 1 μg/mL phytohemagglutinin or 1 μM of TLR9 ligand ODN 2006 (Miltenyi Biotec Ltd) respectively for 24h. Mouse anti-human CD69 antibody 374 
(clone FN50, BioLegend, San Diego, CA, USA) confirmed activation.  375 
 376 
T cell clones 377 
HLA-A*0201 restricted clone MEL5 recognizing peptides EAAGIGILTV and ELAGIGILTV (heteroclitic L at position 2) from Melan A29,30 and a 378 
canonical MAIT clone were cultured as described previously31.  Clone 40E.22 was confirmed as CD1a-restricted using CRISPR-Cas9 ablation of 379 
CD1a, b, c or d (data not shown).  380 
 381 
Mycobacterium smegmatis and Salmonella Typhimurium 382 
Bacterium was grown and used to load phagocytic A549 as previously described37.  383 
 384 
MC.7.G5 isolation and cloning 385 
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PBMCs were isolated by standard density gradient centrifugation and labelled with proliferation dye carboxyfluorescein succinimidyl ester (CFSE) 386 
(eBiosciences™, Thermo Fisher Scientific, Leicestershire, UK) and cultured for two weeks with A549 cells in priming medium (R10 supplemented 387 
with 20 IU/mL IL-2 (Proleukin®; Prometheus, San Diego, CA), 1X MEM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES 388 
buffer (Thermo Fisher Scientific). Primed PBMC were bulk sorted for CFSElow viable CD3+ CD4neg cells on a BD FACS Aria (BD Biosciences, Franklin 389 
Lakes, NJ, USA) and cloned by plating 0.3 cells/well in 96U-well plates.  390 
 391 
T cell activation assays 392 
T cells were rested in R5 (as for R10 with 5% FBS) for 24 h prior to assay. Typically, 3 x104 T cells and 6 x104 target cells were used per well in R5 393 
and incubated overnight, with supernatants harvested for an Enzyme-Linked Immunosorbent Assay (ELISA) (MIP-1β or TNF), which were 394 
performed according to the manufacturer’s instructions (R&D Systems, Biotechne, Minneapolis, MN, US). For antibody blocking assays, target 395 
cells were pre-incubated with anti-MR1 (clone 26.5, BioLegend), pan anti-MHCI (clone W6/32, BioLegend) or pan anti-MHCII (clone Tü39, 396 
BioLegend) antibodies before incubating with T cells. Staining for surface CD107a32 using an anti-CD107a PE Ab (H4A3, BD Biosciences), and 397 
intracellularly with Abs for anti-TNF PE-Vio770 (clone cA2, Miltenyi Biotec Ltd) and anti-IFNγ (clone 45-15, Miltenyi Biotec Ltd), was performed as 398 
described previously31, following activation for 4 h at a T cell to target cell ratio of 1:1. Intracellular cytokine staining (ICS) was performed 399 
according to the manufacturer’s instructions using a Cytofix/Cytoperm kit, GolgiPlug and GolgiStop (BD Biosciences). For tumor necrosis factor 400 
(TNF) processing inhibitor TAPI-0 (Santa Cruz Biotechnology, Dallas, Texas, USA) assays33, T-cells and target cells were co-incubated for 4 h with 401 
30 μM TAPI-0 and antibody directed against TNF (clone cA2, Miltenyi Biotec Ltd.). CD107a antibody (clone H4A3, Miltenyi Biotec Ltd.) was also 402 
 22
included at the start of the assay to detect activation induced degranulation of cytotoxic T-cells32. Following incubation, cells were washed and 403 
stained with Fixable Live/Dead Violet Dye and antibodies against T-cell surface markers. Gating strategy and isotype Ab (as recommended by the 404 
manufacturer of the primary Abs) control experiments for the TAPI-0 assay are shown in Supplementary Fig. 7. Ac-6-FP (Schircks Laboratories, 405 
Switzerland) was reconstituted in DMSO to 50 mg/mL and stored at -20°C protected from light. For MR1 loading Ac-6-FP was incubated 406 
overnight at 37°C and 5% C02 with target cells in their respective media.  407 
 408 
Cytotoxicity assays 409 
For Cr51 release cytotoxicity assays target cells were labelled with chromium-51 (Perkin Elmer, Waltham, Massachusetts, USA) then co-incubated 410 
with T cells at various T cell-to-target ratios for 6 or 18 h and specific lysis calculated, as described previously31. For flow-based killing assays 411 
5,000-10,000 cancer or healthy cell lines were plated in 96U well plates, and MC.7.G5 added to give the desired T cell to cell line ratio 412 
(experimental wells). The cells were co-cultured in 200 μL of target cell media supplemented with 20 IU of IL-2 and 25 ng/mL of IL-15. Targets 413 
cells (control wells), MC.7.G5 and CSFE CIRs were also cultured alone to aid analysis. The cells were incubated for 48 h or 7 d and fed (50% media 414 
change) twice for the latter. Prior to harvest, either BD negative CompBeads (BD Biosciences) (1 drop in 100 μL of PBS then 25 μL per well) or 0.1 415 
x106 CFSE labelled (0.1 μM) CIR cells were added to each well to allow the number of target cells that remained in experimental and control 416 
wells to quantified. The cells were washed 3 times with chilled D-PBS EDTA (2 mM) then stained in the assay plates with Fixable Live/Dead Violet 417 
Dye (VIVID, Thermo Fisher Scientific) then CD3 PerCP (clone UCHT1, BioLegend) and/or anti-TRBV25.1 APC TCR (TRBV11 Arden nomenclature: 418 
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clone C21, Beckman Coulter, Brea, California, USA) Abs to allow dead cells and T cells to be gated-out leaving viable target cells for analyses 419 
(Supplementary Fig. 7). Percentage killing was calculated using the following equation: 420 
%	݈݈݇݅݅݊݃ = 100 −	൭൬݁ݔ݌݁ݎ݅݉݁݊ݐ݈ܽ	ݐܽݎ݃݁ݐ	݈݈ܿ݁	݁ݒ݁݊ݐݏ ÷ ݁ݔ݌݁ݎ݅݉݁݊ݐ݈ܽ	ܾ݁ܽ݀	݋ݎ	ܥܨܵܧ	ܥ1ܴ	݁ݒ݁݊ݐݏܿ݋݊ݐݎ݋݈	ݐܽݎ݃݁ݐ	݈݈ܿ݁	݁ݒ݁݊ݐݏ	 ÷ ܿ݋݊ݐݎ݋݈	ܾ݁ܽ݀	݋ݎ	ܥܨܵܧ	ܥܫܴ	݁ݒ݁݊ݐݏ ൰ × 100൱ 
Flow Cytometry 421 
Cells were stained with Fixable Live/Dead Violet Dye VIVID and the following surface antibodies: pan-αβ TCR PE (clone IP26, BioLegend), pan-γδ 422 
TCR-FITC (clone REA591, Miltenyi Biotec Ltd), CD3 PerCP (clone UCHT1), CD4 APC (clone VIT4, Miltenyi Biotec Ltd), CD8 PE (clone BW135/80, 423 
Miltenyi Biotec Ltd), rat CD2 PE (clone OX-34, BioLegend) and MR1 PE (clone 26.5, BioLegend). For staining with MR1 PE, FcR Block (Miltenyi 424 
Biotec Ltd) was used according to manufacturer’s instructions and isotype Ab as described previously11. For tetramer staining, MR1 monomers 425 
were provided by Jamie Rossjohn (Monash University), and pMHC monomers produced in-house. Tetramers were assembled and used for 426 
optimized staining as described previously31. Cells were gated on lymphocytes (FSC-A versus SSC-A), single cells (FSC-A versus FSC-H) then viable 427 
cells (marker of choice versus VIVID) as show in Supplementary Fig. 7. Data was acquired on a BD FACS Canto II (BD Biosciences) and analysed 428 
with FlowJo software (Tree Star Inc., Ashland, OR, USA). 429 
 430 
MR1 knockout and transgene expression 431 
MR1 single guide (sg)RNA and CRISPR/Cas9 lentivirus was produced and used as described previously37. The native MR1 transgene was cloned 432 
into the second generation pRRL.sin.cppt.pgk-gfp.wpre lentivector backbone developed by Didier Trono’s laboratory (Addgene #12252) devoid 433 
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of the human PGK promoter and GFP cDNA. The codon-optimised MR1 K43A transgene was cloned into the third generation pELNS vector 434 
(kindly provided by James Riley, University of Pennsylvania, PA) devoid of GFP cDNA. Lentiviral particles for native MR1 and MR1 K43A were 435 
produced by calcium chloride transfection of HEK293T cells, as described for MR1 sgRNA37. Target cells were spinfected in the presence of 8 436 
μg/mL polybrene; 500 x g for 2 hours at 37°C32. Anti-MR1 antibody PE (clone 26.5, BioLegend) positive cells were magnetically enriched using 437 
anti-PE magnetic beads according to manufacturer’s instructions (Miltenyi Biotec Ltd).  438 
 439 
TCR sequencing and transduction 440 
MC.7.G5 TCR was sequenced in-house using the SMARTer RACE kit (Takara Bio USA Holdings, Inc, Mountain View, CA, USA) and 2-step 441 
polymerase chain reaction using universal forward primers and reverse primers specific for TCR-α and TCR-β constant regions. The TCR was then 442 
synthesised with codon optimisation (Genewiz, South Plainfield, NJ, USA), with full length α and β TCR chains separated by a ‘self-cleaving’ T2A 443 
sequence33 and cloned in to the third generation pELNS lentiviral vector containing rCD2 as a co-marker (kindly provided by James Riley, 444 
University of Pennsylvania, PA); the β TCR chain was separated from rCD2 by a P2A self-cleavage sequence (Supplementary fig 6). MC.7.G5 TCR-445 
rCD2 pELNs was used to produce virus with envelope plasmid pMD2.G (Addgene plasmid #12259), and packaging plasmids pMDLg/pRRE 446 
(Addgene plasmid #12251) and pRSV-Rev (Addgene plasmid #12253) (all gifts from Didier Trono). Lentiviral particles were generated by calcium 447 
chloride transfection of HEK293T cells and the supernatant 0.4 μm filtered then concentrated by ultra-centrifugation (150,000 g 2h 4°C). The 448 
concentrated lentiviral supernatants were resuspended in T-cell transduction media (as for priming media but with 20% FBS and 25 ng/mL of IL-449 
15 (Miltenyi Biotec Ltd.)), used immediately, or stored at -80°C and only defrosted once before transduction. Post therapy PBMCs were obtained 450 
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from TIL patients MM909.11 and MM909.24 and CD8 and CD4 T cells purified by magnetic enrichment (Miltenyi Biotec Ltd). T cells (1-1.5 x106) 451 
were then activated by overnight incubation with CD3/CD28 beads (Dynabeads; Thermo Fisher Scientific) at a 3:1 bead-to-T cell ratio in 2 mL of 452 
T-cell transduction media in 24 well plates. The following day, 900 μL of the media was removed and replaced with 500 μL of MC.7.G5 TCR 453 
lentivirus supernatant in the presence of 5 μg/mL polybrene (Santa Cruz Biotechnology, Dallas TX, USA). Seven days later, T cells that had taken 454 
up the virus were magnetically enriched with anti-rCD2 PE conjugated antibody and anti-PE magnetic beads, according to manufacturer’s 455 
instructions (Miltenyi Biotec Ltd). Fourteen days post-transduction, T cells were expanded as described previously31 and used for assays after 2 456 
weeks. 457 
 458 
Whole genome GeCKOv.2 screening  459 
Lentiviral particles for the GeCKOv.2 library (plasmid kindly provided by Feng Zhang34 (Addgene plasmid #1000000048)). The GeCKOv.2 library 460 
consists of 123,411 sgRNAs targeting 19,050 protein-coding genes (6 sgRNAs per gene) and 1,864 microRNAs (4 sgRNAs per microRNA) and was 461 
used as lentivirus to transduce the target cell line HEK293T. 4 x107 HEK-293T cells were transduced with a MOI of 0.4 to provide 100X coverage 462 
of each sub-library. Cells that had taken up the lentivirus were selected under puromycin. After 14 days, half the library-containing cells were 463 
frozen as a control. MC.7.G5 was added to remaining transduced HEK-293T cells at a T cell to HEK293T ratio of 0.25:1 in 20 IU IL-2 media. After 464 
14 days, MC.7.G5 was added again at a 0.5:1 ratio. After 7 days the HEK293T cells were used for sequencing. Genomic DNA from 3 x107 of HEK-465 
293T cells (unselected control and selected with MC.7.G5) was isolated (GenElute Mammalian Genomic DNA Miniprep Kit, Sigma-Aldrich, Merck 466 
KGaA, St Louis, Missouri, USA). The entirety of isolated genomic DNA (2.5 μg per 50 μl reaction) was used for subsequent PCR, to ensure 467 
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capturing the full representation of the libraries. The two step PCR was performed as described before (19), using HPLC purified primers and 468 
NEBNext High Fidelity PCR MasterMix (New England Biolabs, Ipswich, MS, USA). The <300 bp PCR products were subsequently isolated from the 469 
agarose gel and sequenced on HiSeq instrument (Illumina, San Diego, CA, USA), with 80 cycles of read 1 (to determine the sequence of sgRNAs) 470 
and 8 cycles of read 2 (to identify sample-specific barcode). Analysis of enriched guides was performed using MAGeCK analysis35. 471 
Cell stress assays 472 
Cells were harvested from culture then incubated with 100-200 μM tert-Butyl hydroperoxide (tBHP) or hydrogen peroxide (H202) for 1h in R10, 473 
followed by staining with CellROX green reagent to detect reactive oxygen species (ROS), according to the manufacturer’s instructions (Thermo 474 
Fisher Scientific). Cells were also stained with viability stain VIVID as above. Caesium source γ-irradiation of cells was performed using a Gamma 475 
Cell irradiator. M. smeg infection of healthy lung epithelial cells was performed as for A549s described above. 476 
 477 
Mouse Experiments 478 
Female JAX™ NOD scid gamma (NSG®) were purchased from Charles Rivers (Wilmington, MA, US) at 6-7 weeks of age, housed under specific 479 
pathogen free conditions and experiments initiated within one week of arrival. Experiments were performed under United Kingdom Home 480 
Office approved projects 30/3188 and P2FB675AB conducted in compliance with the United Kingdom Home Office Guidance on the Operation of 481 
the Animals (Scientific Procedures) Act 1986. Jurkat cells expressing DsRed-Express2 were generated using pELNS vector and lentiviral particles 482 
as described above then cloned. Prior to in vivo transfer Jurkat-DsRed cells and MC.7.G5 were depleted of dead or dying cells by standard 483 
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density gradient centrifugation. Jurkats cells (3 x106) were engrafted first, followed by 1.5 x106 MC.7.G5 7d later. Cells were injected into the tail 484 
vein of mice using a 29G BD microfine syringe in 100 μL of PBS. Mice that did not receive cells were injected with PBS. Each mouse (+/- T cells) 485 
received 5 x104 IU of IL-2 and 50 μg of IL-15 (details as above) via injection into the peritoneal cavity on the day of T cell transfer and every 48h 486 
for the duration of the experiment. Bone marrow was harvested from the tibia and fibula, and splenocytes prepared for staining using standard 487 
density gradient centrifugation. Cells were stained with the viable dye VIVID, followed by antibodies for human CD3 and CD8 (details as above), 488 
and anti-human CD45 APC-Cy7 (clone HI30, BioLegend) and anti-mouse/human CD11b PE-Cy7 (clone M1/70, BD Biosciences) antibodies as 489 
described previously38. Gating strategy for analyses of flow cytometry data is shown in Supplementary Fig. 8. For Jurkat co-transfer experiments, 490 
MR1-/- DsRed-Express2+ Jurkat cells were firstly generated as described above using the MR1 CRISPR-cas9, followed by cloning. 2 x106 WT and 491 
MR1-/- (DsRed-Express2+) Jurkats were transferred to the same mouse, then MC.7.G5 T cells (3 x106) 7d later to the +T cell group. Splenocytes 492 
were harvested at 25d post T cell transfer then incubated with mouse and human FcR block (Miltenyi Biotec Ltd), stained with VIVID and 493 
antibodies for CD3, CD8, CD45, as above, and also with mouse anti-human pan HLA class I (clone W6/32, BioLegend). Survival of mice with Jurkat 494 
cells was assessed by monitoring body weight; mice were culled when they had lost ≥15% of their initial body weight according to United 495 
Kingdom Home Office stipulation.  496 
 497 
Statistical analyses 498 
Neither blinding or randomization was performed for the in vivo studies. A two-sided non-parametric two-sample Kolmogorov-Smirnov test was 499 
used for Jurkat cell burden in NSG mice. The logrank two-sided p value and hazard ratio were calculated using the MatSurv survival analysis 500 
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function in Matlab, available at https://www.github.com/aebergl/MatSurv. The number of mice used in each group is indicated in the respective 501 
figure legend. 502 
 503 
DATA AVAILABILITY  504 
The datasets generated during the current study are available from the corresponding author on reasonable request  505 
 506 
Methods References 507 
 508 
1. Vavassori, S. et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat. Immunol. 14, 908–916 (2013). 509 
2. Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012). 510 
3. Corbett, A. J. et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509, 361–5 (2014). 511 
4. Gold, M. C. et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J. 512 
Exp. Med. 211, 1601–1610 (2014). 513 
5. Eckle, S. B. G. et al. Recognition of Vitamin B precursors and byproducts by mucosal associated invariant T cells. J. Biol. Chem. 290, 30204–514 
30211 (2015). 515 
6. Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701–708 (2010). 516 
7. Reantragoon, R. et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J. Exp. Med. 517 
209, 761–774 (2012). 518 
8. Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ 2 repertoire. Nat. 519 
Commun. 5, 3866 (2014). 520 
9. Lepore, M. et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. Elife 6, 1–22 (2017). 521 
10. Gherardin, N. A. et al. Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition. 522 
Immunity 44, 32–45 (2016). 523 
11. Laugel, B. et al. Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen 524 
 29
Processing and Presentation to Human MR1-Restricted T Cells. J. Immunol. 197, 971–982 (2016). 525 
12. Keller, A. N. et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat. Immunol. (2017). 526 
doi:10.1038/ni.3679 527 
13. Reantragoon, R. et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J. Exp. 528 
Med. 210, 2305–20 (2013). 529 
14. McWilliam, H. E. G. et al. The intracellular pathway for the presentation of vitamin B–related antigens by the antigen-presenting molecule 530 
MR1. Nat. Immunol. advance on, 1–9 (2016). 531 
15. Lamichhane R and Ussher JE. Expression and trafficking of MHC related protein 1 (MR1). J. Immunol. 38, 42–49 (2017). 532 
16. Young, M. H. et al. MAIT Cell Recognition of MR1 on Bacterially Infected and Uninfected Cells. PLoS One 8, e53789 (2013). 533 
17. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015). 534 
18. Gherardin, N. A. et al. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple 535 
myeloma. Sci. Rep. 8, 4159 (2018). 536 
19. Parra-Cuadrado, J. F. et al. A study on the polymorphism of human MHC class I-related MR1 gene and identification of an MR1-like 537 
pseudogene. Tissue Antigens 56, 170–2 (2000). 538 
20. Seshadri, C. et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. Nat. Publ. Gr. 18, 539 
8–14 (2016). 540 
21. Lion, J. et al. MR1B , a natural spliced isoform of the MHC-related 1 protein , is expressed as homodimers at the cell surface and activates 541 
MAIT cells. 1363–1373 (2013). doi:10.1002/eji.201242461 542 
22. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells - supplemenr. Science (80-. ). 343, 84–87 (2014). 543 
23. Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017). 544 
24. Reith, W., LeibundGut-Landmann, S. & Waldburger, J.-M. Regulation of MHC class II gene expression by the class II transactivator. Nat. 545 
Rev. Immunol. 5, 793–806 (2005). 546 
25. Eckle, S. B. G. et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J. Exp. Med. 547 
211, 1585–1600 (2014). 548 
26. Alía, M., Ramos, S., Mateos, R., Bravo, L. & Goya, L. Response of the antioxidant defense system to tert-butyl hydroperoxide and 549 
hydrogen peroxide in a human hepatoma cell line (HepG2). J. Biochem. Mol. Toxicol. 19, 119–128 (2005). 550 
27. Irvine, D. J., Purbhoo, M. A., Krogsgaard, M. & Davis, M. M. Direct observation of ligand recognition by T cells. Nature 419, 845–849 551 
 30
(2002). 552 
28. Hulin-Curtis, S. L. et al. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic 553 
adenovirus. Oncotarget 9, 26328–26341 (2018). 554 
29. Wooldridge, L. et al. MHC Class I Molecules with Superenhanced CD8 Binding Properties Bypass the Requirement for Cognate TCR 555 
Recognition and Nonspecifically Activate CTLs. J. Immunol. 184, 3357–3366 (2010). 556 
30. Lissina, A. et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J. Immunol. 557 
Methods 340, 11–24 (2009). 558 
31. Tungatt, K. et al. Antibody Stabilization of Peptide-MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. J. 559 
Immunol. 194, 463–474 (2014). 560 
32. Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. 561 
Immunol. Methods 281, 65–78 (2003). 562 
33. Haney, D. et al. Isolation of viable antigen-specific CD8+ T cells based on membrane-bound tumor necrosis factor (TNF)-α expression. J. 563 
Immunol. Methods 369, 33–41 (2011). 564 
34. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (80-. ). 343, 84–87 (2014). 565 
35. Ryan, M. D., King, A. M. Q. & Thomas, G. P. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 566 
19 amino acid sequence. J. Gen. Virol. 72, 2727–2732 (1991). 567 
36. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 568 
(2014). 569 
37. Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 570 
554 (2014). 571 
38. Maciocia, P. M. et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat. Med. (2017). 572 
doi:10.1038/nm.4444 573 
 574 








